Loss and reduction of Fus1 protein expression is a frequent phenomenon in the pathogenesis of lung cancer

Ludmila Prudkin, Carmen Behrens, Diane D. Liu, Xian Zhou, Natalie C. Ozburn, B. Nebiyou Bekele, John D. Minna, Cesar Moran, Jack A. Roth, Lin Ji, Ignacio I. Wistuba

Research output: Contribution to journalArticle

58 Citations (Scopus)

Abstract

Purpose: FUS1, a novel tumor-suppressor gene located in the chromosome 3p21.3 region, may play an important role in lung cancer development. Currently, FUS1-expressing nanoparticles have been developed for treating patients with lung cancer. However, the expression of Fus1 protein has not been examined in a large series of lung cancers and their sequential preneoplastic lesions. Experimental Design: Using tissue microarrays, we examined Fus1 immunohistochemical expression in 281 non-small cell lung carcinoma (NSCLC) and 22 small cell lung carcinoma tissue specimens and correlated the findings with patients' clinicopathologic features. To investigate the expression of Fus1 in the early sequential pathogenesis of NSCLC, we studied Fus1 expression in 211 histologically normal and mildly abnormal bronchial epithelia, and 118 bronchial and alveolar preneoplastic lesions obtained from patients with lung cancer. Results: Loss and reduction of expression was detected in 82% of NSCLCs and 100% of small cell lung carcinomas. In NSCLCs, loss of Fus1 immunohistochemical expression was associated with significantly worse overall survival. Bronchial squamous metaplastic and dysplastic lesions expressed significantly lower levels of Fus1 compared with normal (P = 0.014 and 0.047, respectively) and hyperplastic (P = 0.013 and 0.028, respectively) epithelia. Conclusions: Our findings show a high frequency of Fus1 protein loss and reduction of expression in lung cancer, and suggests that this reduction may play an important role in the early pathogenesis of lung squamous cell carcinoma. These findings support the concept that FUS1 gene and Fus1 protein abnormalities could be used to develop newstrategies for molecular cancer therapy for a significant subset of lung tumors.

Original languageEnglish (US)
Pages (from-to)41-47
Number of pages7
JournalClinical Cancer Research
Volume14
Issue number1
DOIs
StatePublished - Jan 1 2008

Fingerprint

Lung Neoplasms
Small Cell Lung Carcinoma
Proteins
Non-Small Cell Lung Carcinoma
Epithelium
Lung
Tumor Suppressor Genes
Nanoparticles
Squamous Cell Carcinoma
Neoplasms
Research Design
Chromosomes
Survival
Therapeutics

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Prudkin, L., Behrens, C., Liu, D. D., Zhou, X., Ozburn, N. C., Bekele, B. N., ... Wistuba, I. I. (2008). Loss and reduction of Fus1 protein expression is a frequent phenomenon in the pathogenesis of lung cancer. Clinical Cancer Research, 14(1), 41-47. https://doi.org/10.1158/1078-0432.CCR-07-1252

Loss and reduction of Fus1 protein expression is a frequent phenomenon in the pathogenesis of lung cancer. / Prudkin, Ludmila; Behrens, Carmen; Liu, Diane D.; Zhou, Xian; Ozburn, Natalie C.; Bekele, B. Nebiyou; Minna, John D.; Moran, Cesar; Roth, Jack A.; Ji, Lin; Wistuba, Ignacio I.

In: Clinical Cancer Research, Vol. 14, No. 1, 01.01.2008, p. 41-47.

Research output: Contribution to journalArticle

Prudkin, L, Behrens, C, Liu, DD, Zhou, X, Ozburn, NC, Bekele, BN, Minna, JD, Moran, C, Roth, JA, Ji, L & Wistuba, II 2008, 'Loss and reduction of Fus1 protein expression is a frequent phenomenon in the pathogenesis of lung cancer', Clinical Cancer Research, vol. 14, no. 1, pp. 41-47. https://doi.org/10.1158/1078-0432.CCR-07-1252
Prudkin, Ludmila ; Behrens, Carmen ; Liu, Diane D. ; Zhou, Xian ; Ozburn, Natalie C. ; Bekele, B. Nebiyou ; Minna, John D. ; Moran, Cesar ; Roth, Jack A. ; Ji, Lin ; Wistuba, Ignacio I. / Loss and reduction of Fus1 protein expression is a frequent phenomenon in the pathogenesis of lung cancer. In: Clinical Cancer Research. 2008 ; Vol. 14, No. 1. pp. 41-47.
@article{1d5613cf630a447a8d160a12f2688cdf,
title = "Loss and reduction of Fus1 protein expression is a frequent phenomenon in the pathogenesis of lung cancer",
abstract = "Purpose: FUS1, a novel tumor-suppressor gene located in the chromosome 3p21.3 region, may play an important role in lung cancer development. Currently, FUS1-expressing nanoparticles have been developed for treating patients with lung cancer. However, the expression of Fus1 protein has not been examined in a large series of lung cancers and their sequential preneoplastic lesions. Experimental Design: Using tissue microarrays, we examined Fus1 immunohistochemical expression in 281 non-small cell lung carcinoma (NSCLC) and 22 small cell lung carcinoma tissue specimens and correlated the findings with patients' clinicopathologic features. To investigate the expression of Fus1 in the early sequential pathogenesis of NSCLC, we studied Fus1 expression in 211 histologically normal and mildly abnormal bronchial epithelia, and 118 bronchial and alveolar preneoplastic lesions obtained from patients with lung cancer. Results: Loss and reduction of expression was detected in 82{\%} of NSCLCs and 100{\%} of small cell lung carcinomas. In NSCLCs, loss of Fus1 immunohistochemical expression was associated with significantly worse overall survival. Bronchial squamous metaplastic and dysplastic lesions expressed significantly lower levels of Fus1 compared with normal (P = 0.014 and 0.047, respectively) and hyperplastic (P = 0.013 and 0.028, respectively) epithelia. Conclusions: Our findings show a high frequency of Fus1 protein loss and reduction of expression in lung cancer, and suggests that this reduction may play an important role in the early pathogenesis of lung squamous cell carcinoma. These findings support the concept that FUS1 gene and Fus1 protein abnormalities could be used to develop newstrategies for molecular cancer therapy for a significant subset of lung tumors.",
author = "Ludmila Prudkin and Carmen Behrens and Liu, {Diane D.} and Xian Zhou and Ozburn, {Natalie C.} and Bekele, {B. Nebiyou} and Minna, {John D.} and Cesar Moran and Roth, {Jack A.} and Lin Ji and Wistuba, {Ignacio I.}",
year = "2008",
month = "1",
day = "1",
doi = "10.1158/1078-0432.CCR-07-1252",
language = "English (US)",
volume = "14",
pages = "41--47",
journal = "Clinical Cancer Research",
issn = "1078-0432",
publisher = "American Association for Cancer Research Inc.",
number = "1",

}

TY - JOUR

T1 - Loss and reduction of Fus1 protein expression is a frequent phenomenon in the pathogenesis of lung cancer

AU - Prudkin, Ludmila

AU - Behrens, Carmen

AU - Liu, Diane D.

AU - Zhou, Xian

AU - Ozburn, Natalie C.

AU - Bekele, B. Nebiyou

AU - Minna, John D.

AU - Moran, Cesar

AU - Roth, Jack A.

AU - Ji, Lin

AU - Wistuba, Ignacio I.

PY - 2008/1/1

Y1 - 2008/1/1

N2 - Purpose: FUS1, a novel tumor-suppressor gene located in the chromosome 3p21.3 region, may play an important role in lung cancer development. Currently, FUS1-expressing nanoparticles have been developed for treating patients with lung cancer. However, the expression of Fus1 protein has not been examined in a large series of lung cancers and their sequential preneoplastic lesions. Experimental Design: Using tissue microarrays, we examined Fus1 immunohistochemical expression in 281 non-small cell lung carcinoma (NSCLC) and 22 small cell lung carcinoma tissue specimens and correlated the findings with patients' clinicopathologic features. To investigate the expression of Fus1 in the early sequential pathogenesis of NSCLC, we studied Fus1 expression in 211 histologically normal and mildly abnormal bronchial epithelia, and 118 bronchial and alveolar preneoplastic lesions obtained from patients with lung cancer. Results: Loss and reduction of expression was detected in 82% of NSCLCs and 100% of small cell lung carcinomas. In NSCLCs, loss of Fus1 immunohistochemical expression was associated with significantly worse overall survival. Bronchial squamous metaplastic and dysplastic lesions expressed significantly lower levels of Fus1 compared with normal (P = 0.014 and 0.047, respectively) and hyperplastic (P = 0.013 and 0.028, respectively) epithelia. Conclusions: Our findings show a high frequency of Fus1 protein loss and reduction of expression in lung cancer, and suggests that this reduction may play an important role in the early pathogenesis of lung squamous cell carcinoma. These findings support the concept that FUS1 gene and Fus1 protein abnormalities could be used to develop newstrategies for molecular cancer therapy for a significant subset of lung tumors.

AB - Purpose: FUS1, a novel tumor-suppressor gene located in the chromosome 3p21.3 region, may play an important role in lung cancer development. Currently, FUS1-expressing nanoparticles have been developed for treating patients with lung cancer. However, the expression of Fus1 protein has not been examined in a large series of lung cancers and their sequential preneoplastic lesions. Experimental Design: Using tissue microarrays, we examined Fus1 immunohistochemical expression in 281 non-small cell lung carcinoma (NSCLC) and 22 small cell lung carcinoma tissue specimens and correlated the findings with patients' clinicopathologic features. To investigate the expression of Fus1 in the early sequential pathogenesis of NSCLC, we studied Fus1 expression in 211 histologically normal and mildly abnormal bronchial epithelia, and 118 bronchial and alveolar preneoplastic lesions obtained from patients with lung cancer. Results: Loss and reduction of expression was detected in 82% of NSCLCs and 100% of small cell lung carcinomas. In NSCLCs, loss of Fus1 immunohistochemical expression was associated with significantly worse overall survival. Bronchial squamous metaplastic and dysplastic lesions expressed significantly lower levels of Fus1 compared with normal (P = 0.014 and 0.047, respectively) and hyperplastic (P = 0.013 and 0.028, respectively) epithelia. Conclusions: Our findings show a high frequency of Fus1 protein loss and reduction of expression in lung cancer, and suggests that this reduction may play an important role in the early pathogenesis of lung squamous cell carcinoma. These findings support the concept that FUS1 gene and Fus1 protein abnormalities could be used to develop newstrategies for molecular cancer therapy for a significant subset of lung tumors.

UR - http://www.scopus.com/inward/record.url?scp=40749138663&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=40749138663&partnerID=8YFLogxK

U2 - 10.1158/1078-0432.CCR-07-1252

DO - 10.1158/1078-0432.CCR-07-1252

M3 - Article

VL - 14

SP - 41

EP - 47

JO - Clinical Cancer Research

JF - Clinical Cancer Research

SN - 1078-0432

IS - 1

ER -